Wrapping up Q3 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including GoodRx ...

Fintel reports that on January 22, 2026, Jefferies downgraded their outlook for GoodRx Holdings (NasdaqGS:GDRX) from Buy to ...

Analysts have recently evaluated GoodRx Holdings and provided 12-month price targets. The average target is $4.16, accompanied by a high estimate of $6.00 and a low estimate of $2.75. This current ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock could revive after a 91% fall from its peak.

Last year was not a good one for Dexcom ( DXCM +2.51%). The medical device specialist lagged the market, and even with a bit ...

Key Insights Significant control over GoodRx Holdings by individual investors implies that the general public has ...

Surescripts®, the nation’s leading health intelligence network, introduces its Patient Experience product, Script Corner™, to ...

Additionally, Morgan Stanley reduced its price target for GoodRx from $5 to $4 while maintaining an Equal Weight rating on December 18. In a 2026 outlook for the Healthcare Services sector, the firm ...

GoodRX, Weight Watchers and LifeMD all said they will offer Novo Nordisk's new weight-loss pill, Wegovy, on their respective platforms. U.S. regulators approved the new pill last month. At that time, ...

GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that the newly FDA-approved Wegovy® pill (oral semaglutide) is now available at a cash price of $149 per ...